[1] Dennett CC, Simon J. The role of polycystic ovary syndrome in reproductive and metabolic health: Overview and approaches for treatment. Diabetes Spectr 2015; 28: 116-120.

[2] Escobar-Morreale HF. Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 2018; 14: 270-284.

[3] Abbott DH, Kraynak M, Dumesic DA, Levine JE. In utero androgen excess: A developmental commonality preceding polycystic ovary syndrome? Front Horm Res 2019; 53: 1-17.

[4] Bahreiny SS, Ahangarpour A, Amraei M, Mansouri Z, Pirsadeghi A, Kazemzadeh R, et al. Autoimmune thyroid disorders and polycystic ovary syndrome: Tracing links through systematic review and meta-analysis. J Reprod Immunol 2024; 163: 104215.

[5] Hudecova M, Holte J, Olovsson M, Larsson A, Berne C, Sundstrom-Poromaa I. Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: Long-term follow-up. Fertil Steril 2011; 96: 1271-1274.

[6] De Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: A systematic review and meta-analysis. Hum Reprod Update 2011; 17: 495-500.

[7] Mancini A, Bruno C, Vergani E, d’Abate C, Giacchi E, Silvestrini A. Oxidative stress and low-grade inflammation in polycystic ovary syndrome: Controversies and new insights. Int J Mol Sci 2021; 22: 1667.

[8] Mizgier M, Jarząbek-Bielecka G, Wendland N, Jodłowska-Siewert E, Nowicki M, Brożek A, et al. Relation between inflammation, oxidative stress, and macronutrient intakes in normal and excessive body weight adolescent girls with clinical features of polycystic ovary syndrome. Nutrients 2021; 13: 896.

[9] Stichtenoth DO, Frölich JC. Nitric oxide and inflammatory joint diseases. Br J Rheumatol 1998; 37: 246-257.

[10] Somasundaram V, Basudhar D, Bharadwaj G, No JH, Ridnour LA, Cheng RY, et al. Molecular mechanisms of nitric oxide in cancer progression, signal transduction, and metabolism. Antioxid Redox Signal 2019; 30: 1124-1143.

[11] Stadler K. Peroxynitrite-driven mechanisms in diabetes and insulin resistance-the latest advances. Curr Med Chem 2011; 18: 280-290.

[12] Rai N, Dey S. Protective response of sestrin under stressful conditions in aging. Ageing Res Rev 2020; 64: 101186.

[13] Sun W, Wang Y, Zheng Y, Quan N. The emerging role of sestrin2 in cell metabolism, and cardiovascular and age-related diseases. Aging Dis 2020; 11: 154-163.

[14] Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL. Oxidative stress in atherosclerosis. Curr Atheroscler Rep 2017; 19: 42.

[15] Steven S, Frenis K, Oelze M, Kalinovic S, Kuntic M, Bayo Jimenez MT, et al. Vascular inflammation and oxidative stress: Major triggers for cardiovascular disease. Oxid Med Cell Longev 2019; 2019: 7092151.

[16] Daenen K, Andries A, Mekahli D, Van Schepdael A, Jouret F, Bammens B. Oxidative stress in chronic kidney disease. Pediatr Nephrol 2019; 34: 975-991.

[17] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.

[18] Bahreiny SS, Ahangarpour A, Saki N, Dabbagh MR, Ebrahimi R, Mahdizade AH, et al. Association of free radical product and polycystic ovary syndrome: A systematic review and meta-analysis. Reprod Sci 2024; 31: 1486-1495.

[19] Bahreiny SS, Aghaei M, Dabbagh MR, Ghorbani H, Javidan M, Fard RM. Exploring the relationship between ambient sulfur dioxide and semen quality parameters: A systematic review and meta-analysis. Asian Pacific J Reprod 2024; 13: 12-21.

[20] Bahreiny SS, Bastani M-N, Aghaei M, Dabbagh MR, Mahdizade AH. Circulating galectin-3 levels in women with polycystic ovary syndrome: A meta-analysis. Taiwan J Obstet Gynecol 2024; 63: 37-45.

[21] Bahreiny SS, Bastani M-N, Dabbagh MR, Ghorbani H, Aghaei M, Zahedian M, et al. Association between ambient particulate matter and semen quality parameters: A systematic review and meta-analysis. Middle East Fertil Soc J 2024; 29: 2.

[22] Lakshmi K, Malini S. Relationship between serum levels of oxidative stress markers and metabolic syndrome components in PCOS women. J Endocrinol Reprod 2023; 27: 29-39.

[23] Yeşil F, Deveci K, Karli P. Evaluation of the clinical significance of serum pentraxin-3 levels in patients with polycystic ovary syndrome. Clin Exp Obstet Gynecol 2022; 49: 38.

[24] Kohzadi M, Khazaei MR, Choobsaz F, Khazaei M. Relationship between serum levels of anti-mullerian hormone, adiponectin and oxidative stress markers in patients with polycystic ovary syndrome. Int J Fertil Steril 2020; 14: 27-33.

[25] Krishna MB, Joseph A, Thomas PL, Dsilva B, Pillai SM, Laloraya M. Impaired arginine metabolism coupled to a defective redox conduit contributes to low plasma nitric oxide in polycystic ovary syndrome. Cell Physiol Biochem 2017; 43: 1880-1892.

[26] Kocer D, Bayram F, Diri H. The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome. Gynecol Endocrinol 2014; 30: 367-371.

[27] Yavuz Taşlipinar M, Kiliç N, Bayraktar N, Güler İ, Gülcan Kurt Y, Göktaş T, et al. Endothelial dysfunction and insulin resistance in young women with polycystic ovarian syndrome. Turk J Med Sci 2014; 44: 787-791.

[28] Willis GR, Udiawar M, Evans WD, Blundell HL, James PE, Rees DA. Detailed characterisation of circulatory nitric oxide and free radical indices-is there evidence for abnormal cardiovascular homeostasis in young women with polycystic ovary syndrome? BJOG 2014; 121: 1596-1603.

[29] Su Y. Determination and clinical application of serum NO, SOD, and MDA in patients with polycystic ovary syndrome

[M.Sc. thesis]. China: Dali University; 2012.

[30] Karadeniz M, Erdoğan M, Ayhan Z, Yalcin M, Olukman M, Cetinkalp S, et al. Effect of G2706A and G1051A polymorphisms of the ABCA1 gene on the lipid, oxidative stress and homocystein levels in Turkish patients with polycystıc ovary syndrome. Lipids Health Dis 2011; 10: 193.

[31] Bayram F, Kocer D, Ozsan M, Muhtaroglu S. Evaluation of endothelial dysfunction, lipid metabolism in women with polycystic ovary syndrome: Relationship of paraoxonase 1 activity, malondialdehyde levels, low-density lipoprotein subfractions, and endothelial dysfunction. Gynecol Endocrinol 2012; 28: 497-501.

[32] Baskol G, Aygen E, Erdem F, Caniklioğlu A, Narin F, Sahin Y, et al. Assessment of paraoxonase 1, xanthine oxidase and glutathione peroxidase activities, nitric oxide and thiol levels in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 2012; 91: 326-330.

[33] Türkçüoğlu I, Engin-Üstün Y, Turan F, Kali Z, Karabulut AB, Meydanli M, et al. Evaluation of asymmetric dimethylarginine, nitric oxide levels and associated independent variables in obese and lean patients with polycystic ovarian syndrome. Gynecol Endocrinol 2011; 27: 609-614.

[34] Erdogan M, Karadeniz M, Berdeli A, Alper G, Caglayan O, Yilmaz C. The relationship of the interleukin-6-174 G> C gene polymorphism with oxidative stress markers in Turkish polycystic ovary syndrome patients. J Endocrinol Invest 2008; 31: 624-629.

[35] Guan Y, Yang X, Ren F. Clinical study on the serum nitric oxide and related factors in women with PCOS. Chinese J Clin Obstet Gynecol 2008; 9: 217-219.

[36] Bahreiny SS, Dabbagh MR, Ebrahimi R, Harooni E. Prevalence of autoimmune thyroiditis in women with polycystic ovary syndrome: A systematic review and meta-analysis. Iran J Obstet Gynecol Infertil 2023; 26: 94-106. (in Persian)

[37] Bahreiny SS, Ahangarpour A, Hemmati AA, Kazemzadeh R, Bastani M-N, Dabbagh MR, et al. Circulating nesfatin-1 levels in women with polycystic ovary syndrome: A systematic review and meta-analysis. Int J Reprod BioMed 2023; 21: 777-788.

[38] Ahmad A, Dempsey SK, Daneva Z, Azam M, Li N, Li PL, et al. Role of nitric oxide in the cardiovascular and renal systems. Int J Mol Sci 2018; 19: 2605.

[39] Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: Testing and clinical relevance. Circulation 2007; 115: 1285-1295.

[40] Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001; 103: 1410-1415.

[41] Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.

[42] Mahdizade AH, Bahreiny SS, Bastani M-N, Dabbagh MR, Aghaei M, Ali Malayeri F, et al. The influence of CDKAL1 (rs7754840) gene polymorphism on susceptibility to gestational diabetes mellitus in pregnant women: A systematic review and meta-analysis. Int J Diabetes Develop Countries 2024; 44: 3-12.

[43] Mather KJ, Steinberg HO, Baron AD. Insulin resistance in the vasculature. J Clin Invest 2013; 123: 1003-1004.

[44] Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocr Rev 2012; 33: 981-1030.

[45] Yildirim B, Sabir N, Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil Steril 2003; 79: 1358-1364.

[46] Mohammadpour Fard R, Rashno M, Bahreiny SS. Effects of melatonin supplementation on markers of inflammation and oxidative stress in patients with diabetes: A systematic review and meta-analysis of randomized controlled trials. Clinl Nutr ESPEN 2024; 63: 530-539.

[47] González F. Inflammation in polycystic ovary syndrome: Underpinning of insulin resistance and ovarian dysfunction. Steroids 2012; 77: 300-305.

[48] Macut D, Bjekić-Macut J, Savić-Radojević A. Dyslipidemia and oxidative stress in PCOS. Front Horm Res 2013; 40: 51-63.

[49] Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocrine Rev 2007; 28: 463-491.

[50] Orio Jr F, Palomba S, Cascella T, Milan G, Mioni R, Pagano C, et al. Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 2619-2623.

[51] Sydow K, Münzel T. ADMA and oxidative stress. Atheroscler Suppl 2003; 4: 41-51.

[52] Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN, et al. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem 2002; 277: 1794-1799.

[53] Etgen Jr GJ, Fryburg DA, Gibbs EM. Nitric oxide stimulates skeletal muscle glucose transport through a calcium/ contraction- and phosphatidylinositol-3-kinaseindependent pathway. Diabetes 1997; 46: 1915-1919.

[54] Bahreiny SS, Ahangarpour A, Aghaei M. Circulating levels of advanced glycation end products in females with polycystic ovary syndrome: A meta-analysis. Reprod Dev Med 2024; 8: 93-100.

[55] Esposito K, Pontillo A, Giugliano F, Giugliano G, Marfella R, Nicoletti G, et al. Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab 2003; 88: 1055-1058.

[56] Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 2007; 87: 507-520.

[57] Aghaei M, Khademi R, Far MAJ, Bahreiny SS, Mahdizade AH, Amirrajab N. Genetic variants of dectin-1 and their antifungal immunity impact in hematologic malignancies: A comprehensive systematic review. Curr Res Transl Med 2024; 72: 103460.

[58] Luo Y, Zhu Y, Basang W, Wang X, Li C, Zhou X. Roles of nitric oxide in the regulation of reproduction: A review. Front Endocrinol 2021; 12: 752410.

[59] Zhao H, Zhang J, Cheng X, Nie X, He B. Insulin resistance in polycystic ovary syndrome across various tissues: An updated review of pathogenesis, evaluation, and treatment. J Ovarian Res 2023; 16: 9.

[60] Meinhardt UJ, Ho KK. Modulation of growth hormone action by sex steroids. Clin Endocrinol 2006; 65: 413-422.

[61] Tewari D, Sah AN, Bawari S, Nabavi SF, Dehpour AR, Shirooie S, et al. Role of nitric oxide in neurodegeneration: Function, regulation, and inhibition. Curr Neuropharmacol 2021; 19: 114-126.